255 related articles for article (PubMed ID: 18723297)
1. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03.
Tsien C; Moughan J; Michalski JM; Gilbert MR; Purdy J; Simpson J; Kresel JJ; Curran WJ; Diaz A; Mehta MP;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):699-708. PubMed ID: 18723297
[TBL] [Abstract][Full Text] [Related]
2. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
[TBL] [Abstract][Full Text] [Related]
3. Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.
Langer CJ; Ruffer J; Rhodes H; Paulus R; Murray K; Movsas B; Curran W
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):113-9. PubMed ID: 11516860
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023.
Cardinale R; Won M; Choucair A; Gillin M; Chakravarti A; Schultz C; Souhami L; Chen A; Pham H; Mehta M
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1422-8. PubMed ID: 16750317
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.
Souhami L; Seiferheld W; Brachman D; Podgorsak EB; Werner-Wasik M; Lustig R; Schultz CJ; Sause W; Okunieff P; Buckner J; Zamorano L; Mehta MP; Curran WJ
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):853-60. PubMed ID: 15465203
[TBL] [Abstract][Full Text] [Related]
6. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
[TBL] [Abstract][Full Text] [Related]
7. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
Morganti AG; Balducci M; Salvati M; Esposito V; Romanelli P; Ferro M; Calista F; Digesù C; Macchia G; Ianiri M; Deodato F; Cilla S; Piermattei A; Valentini V; Cellini N; Cantore GP
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):92-7. PubMed ID: 19683876
[TBL] [Abstract][Full Text] [Related]
8. Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
Rudra S; Hui C; Rao YJ; Samson P; Lin AJ; Chang X; Tsien C; Fergus S; Mullen D; Yang D; Thotala D; Hallahan D; Campian JL; Huang J
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):217-225. PubMed ID: 29502931
[TBL] [Abstract][Full Text] [Related]
9. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
12. Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.
Balducci M; Apicella G; Manfrida S; Mangiola A; Fiorentino A; Azario L; D'Agostino GR; Frascino V; Dinapoli N; Mantini G; Albanese A; de Bonis P; Chiesa S; Valentini V; Anile C; Cellini N
Strahlenther Onkol; 2010 Oct; 186(10):558-64. PubMed ID: 20936460
[TBL] [Abstract][Full Text] [Related]
13. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study.
Piroth MD; Pinkawa M; Holy R; Klotz J; Schaar S; Stoffels G; Galldiks N; Coenen HH; Kaiser HJ; Langen KJ; Eble MJ
Strahlenther Onkol; 2012 Apr; 188(4):334-9. PubMed ID: 22349712
[TBL] [Abstract][Full Text] [Related]
14. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394.
Grossman SA; O'Neill A; Grunnet M; Mehta M; Pearlman JL; Wagner H; Gilbert M; Newton HB; Hellman R;
J Clin Oncol; 2003 Apr; 21(8):1485-91. PubMed ID: 12697871
[TBL] [Abstract][Full Text] [Related]
15. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
16. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
[TBL] [Abstract][Full Text] [Related]
17. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial.
Sultanem K; Patrocinio H; Lambert C; Corns R; Leblanc R; Parker W; Shenouda G; Souhami L
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):247-52. PubMed ID: 14697445
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
Buckner JC; Ballman KV; Michalak JC; Burton GV; Cascino TL; Schomberg PJ; Hawkins RB; Scheithauer BW; Sandler HM; Marks RS; O'Fallon JR; ;
J Clin Oncol; 2006 Aug; 24(24):3871-9. PubMed ID: 16921039
[TBL] [Abstract][Full Text] [Related]
19. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ
J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study.
Brandes AA; Rigon A; Zampieri P; Ermani M; Carollo C; Altavilla G; Turazzi S; Chierichetti F; Florentino MV
Cancer; 1998 Jan; 82(2):355-61. PubMed ID: 9445194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
